Thursday, April 16, 2026 – THURSDAY, April 16, 2026 — Social media posts about glucagon-like peptide-1 receptor agonists may identify patient concerns not captured in clinical trials, according to a study published online April 10 in Nature Health.Neil K.R. Sehgal, from the…

Thursday, April 16, 2026 – Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn’t actually necessary to achieve effective weight loss.

Thursday, April 16, 2026 – As more people turn to prescription drugs for smaller weight-loss goals, one writer explores the pros and cons.

Thursday, April 16, 2026 – Friday, April 17 – A recent poll found 1 in 8 adults take a GLP-1 medication like Ozempic or Wegovy and 27 percent of those users said even though they have insurance, they still pay out-of-pocket for those drugs. NBC News medical contributor Dr. Natalie Azar and chief business correspondent Christine Romans join TODAY to break down the different weight loss drugs, how to know if your insurance will cover them and more.

Wednesday, April 15, 2026 – Thursday, April 16 – Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.

Wednesday, April 15, 2026 – Thursday, April 16 – If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight loss journey on GLP-1 medications in a commercial.

Wednesday, April 15, 2026 – Thursday, April 16 – Over the past few years, GLP-1 receptor agonists have been growing in popularity for weight loss.

While many people lose between 5-15% of their starting body weight while on a GLP-1, as much as 20% of people may not respond to the drug.

Recent research has found that a person’s genetic makeup may explain why some people do not respond to GLP-1 drugs.

A new review suggests that taking both a GLP-1 medication, and a medication that combines both naltrexone and bupropion into one pill, may be helpful for those who are not responding to GLP-1s alone.

Wednesday, April 15, 2026 – Wednesday, April 15 – A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn’t yet shown the health impacts of cycling on and off the drugs.

Tuesday, April 14, 2026 – Wednesday, April 15 – (MedPage Today) — Eating the same meals every day may aid in weight loss, according to a study of real-time food tracking data. (Health Psychology)
The prevalence of youth-onset type 2 diabetes increased substantially from 2013 to 2024, rising…

Tuesday, April 14, 2026 – Wednesday, April 15 – Research has found that the effectiveness of GLP-1 drugs may vary based on a person’s genetics. Image Credit: Indranil MUKHERJEE / AFP via Getty Images

GLP-1 medications may not always be effective for everyone.

New research suggests that around 10% of people carry genetic variations that explain why. 

Tuesday, April 14, 2026 – Wednesday, April 15 – Researchers at Toronto’s Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve organ function and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease.

Tuesday, April 14, 2026 – Wednesday, April 15 – With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.

Tuesday, April 14, 2026 – Tuesday, April 14 – Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading…

Monday, April 13, 2026 – Tuesday, April 14 – — Your genetics might play a role in how well cutting-edge weight loss drugs like Ozempic and Zepbound will work for you, a new study says.Specific genetic traits can affect both weight loss and side effects for people taking…

Monday, April 13, 2026 – Tuesday, April 14 – Amazon will offer the new GLP-1 pill, Foundayo, via kiosks and same-day delivery. Image credit: Michael Nagle/Bloomberg via Getty Images

Eli Lilly has announced the availability of the new GLP-1 pill, Foundayo, through Amazon One Medical kiosks. .

Monday, April 13, 2026 – Monday, April 13 – A newly discovered molecule could reshape the future of weight loss treatments by mimicking the powerful appetite-suppressing effects of drugs like Ozempic — but without many of the unpleasant side effects. Identified using artificial intelligence, this tiny peptide, called BRP, appears to act directly on the brain’s appetite-control center, helping animals eat less and lose fat without nausea or muscle loss.

Sunday, April 12, 2026 – Monday, April 13 – A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.

Saturday, April 11, 2026 – Saturday, April 11 – More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

Friday, April 10, 2026 – Saturday, April 11 – (MedPage Today) — GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.
Using U.S. electronic health record data, the incidence of…

Friday, April 10, 2026 – Saturday, April 11 – Here’s everything we know so far.

Friday, April 10, 2026 – Saturday, April 11 – New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include …

Friday, April 10, 2026 – Friday, April 10 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

Friday, April 10, 2026 – Friday, April 10 – → A decorated GLP-1 pioneer is retiring at Novo Nordisk.

Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the …

Friday, April 10, 2026 – Friday, April 10 – Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.

Thursday, April 9, 2026 – Friday, April 10 – Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

Thursday, April 9, 2026 – Friday, April 10 – (MedPage Today) — Integrating the most effective obesity treatments into cancer survivorship offers “an unprecedented opportunity” to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in…

Thursday, April 9, 2026 – Friday, April 10 – The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout

Thursday, April 9, 2026 – Friday, April 10 – Steve Ubl, chief executive of PhRMA, plans to step down at the end of the ‌year, after more than a decade leading the main trade group for brand-name drug makers

Wednesday, April 8, 2026 – Thursday, April 9 – 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.

Wednesday, April 8, 2026 – Thursday, April 9 – Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.

Wednesday, April 8, 2026 – Thursday, April 9 –

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — In a whistleblower lawsuit, a prominent cardiologist says he was fired from the University of Pittsburgh Medical Center (UPMC) after reporting racist text messages exchanged between colleagues and a potential conflict of interest…

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month…

Tuesday, April 7, 2026 – Wednesday April 8 – Plus, news about Vertex and Halozyme, Werewolf, and Regeneron:

Novo Nordisk launches high-dose Wegovy in the US: The 7.2 mg injectable form of the GLP-1 agonist is now available in the US to treat obesity …

Tuesday, April 7, 2026 – Wednesday April 8 – Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout

Tuesday, April 7, 2026 – Wednesday April 8 – The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly

Federal regulators have approved the GLP-1 tablet Foundayo for use in weight management.

Experts say having another weight loss medication in pill form could help people stick to a weight management regimen.

Monday, April 6, 2026 – MONDAY, April 6, 2026 — Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the…

Monday, April 6, 2026 – Tuesday, April 7 – Combat muscle loss with this 7-move routine.

Monday, April 6, 2026 – Tuesday, April 7 – Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Monday, April 6, 2026 – Tuesday, April 7 – Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.